Cataract Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
CATARACT THERAPEUTICS PIPELINE ANALYSIS
• Cataract is defined as a type of disease that occurs due to the clouding of the eye’s natural lens, which lies behind iris and pupil.
• Cataract was known to start at any age, and sometimes, it can be present from birth also. The eye lens is transparent and light sensitive and is located at the back of the eye. It helps to focus light rays on the retina, which aids in the formation of a clear image.
• Images at retina are converted into optic signals that are then communicated to the brain. Eye lens consists of protein and water, as a person grows old, the protein gets clump together and starts to form a cloud that continues to grow, makes patient harder to see.
• Symptoms are the clouded, blurred or dim vision, fading or yellowing of colors, double vision in a single eye, increasing difficulty with vision at night, and frequent prescription changes in eyewear.
• Risk factors include age, diabetes, high blood pressure, obesity, drinking excessive amounts of alcohol, and smoking.
• The affected cataract people show the color of eye lens changing to brown, adding a brownish tint to their vision. Consumption of unhygienic crops and fruits, rising level of pollutants in the environment, and the unhealthy lifestyle are some of the other important factors responsible for the increased incidence of cataract disease.
• The acquisition also included accession of ophthalmic products in three business segments such as cataract surgery, laser refractive surgery, and consumer eye health.
• Companies are targeting developing molecules with heat shock proteins, also known as alpha crystalline, that prevents aggregation in the lens of the eye by misfolded proteins.
• For instance, Plex Pharmaceuticals developed a novel compound, which is an alpha crystalline activator that helps in maintaining the proper refractive index in the lens.
• Many companies that conduct clinical studies are going to evaluate the safety and efficacy of drugs in the treatment of cataract disease.
• For example, Bromfenac ophthalmic solution by Bausch & Lomb Incorporated is in the clinical Phase III, DYME by Aqumen Biopharmaceuticals, N.A. is in Phase III, DE-108 by Santen Pharmaceutical Co., Ltd., in clinical Phase III, C-KAD Ophthalmic Solution by Chakshu Research, Inc. in clinical Phase II, and OMS302 by Omeros Corporation is in the clinical Phase I/II. A New Drug Application submitted by Icon Bioscience Inc. (Icon) to the United States Food and Drug Administration for the drug IBI-10090 is for the treatment of inflammation accompanied by post-operative cataract surgery.
• IBI-10090 is an anti-inflammatory-biodegradable extended-release formulation, injected during eye surgery in the chamber of the eye with the help of Icon’s Varisome drug-delivery technology.
• The increase in the occurrence of cataract diseases and technological advancements in ophthalmic devices drive the market growth. In addition, the hike in the geriatric population worldwide boosts the market growth.
• Need for healthcare insurance and lack of awareness among individuals regarding the benefits impede the growth of the cataract therapeutics market.
• Moreover, the burden of cataract-related diseases is reduced by introducing government programs are lucrative opportunities for key market players.
• Cataract is defined as a type of disease that occurs due to the clouding of the eye’s natural lens, which lies behind iris and pupil.
• Cataract was known to start at any age, and sometimes, it can be present from birth also. The eye lens is transparent and light sensitive and is located at the back of the eye. It helps to focus light rays on the retina, which aids in the formation of a clear image.
• Images at retina are converted into optic signals that are then communicated to the brain. Eye lens consists of protein and water, as a person grows old, the protein gets clump together and starts to form a cloud that continues to grow, makes patient harder to see.
• Symptoms are the clouded, blurred or dim vision, fading or yellowing of colors, double vision in a single eye, increasing difficulty with vision at night, and frequent prescription changes in eyewear.
• Risk factors include age, diabetes, high blood pressure, obesity, drinking excessive amounts of alcohol, and smoking.
• The affected cataract people show the color of eye lens changing to brown, adding a brownish tint to their vision. Consumption of unhygienic crops and fruits, rising level of pollutants in the environment, and the unhealthy lifestyle are some of the other important factors responsible for the increased incidence of cataract disease.
• The acquisition also included accession of ophthalmic products in three business segments such as cataract surgery, laser refractive surgery, and consumer eye health.
• Companies are targeting developing molecules with heat shock proteins, also known as alpha crystalline, that prevents aggregation in the lens of the eye by misfolded proteins.
• For instance, Plex Pharmaceuticals developed a novel compound, which is an alpha crystalline activator that helps in maintaining the proper refractive index in the lens.
• Many companies that conduct clinical studies are going to evaluate the safety and efficacy of drugs in the treatment of cataract disease.
• For example, Bromfenac ophthalmic solution by Bausch & Lomb Incorporated is in the clinical Phase III, DYME by Aqumen Biopharmaceuticals, N.A. is in Phase III, DE-108 by Santen Pharmaceutical Co., Ltd., in clinical Phase III, C-KAD Ophthalmic Solution by Chakshu Research, Inc. in clinical Phase II, and OMS302 by Omeros Corporation is in the clinical Phase I/II. A New Drug Application submitted by Icon Bioscience Inc. (Icon) to the United States Food and Drug Administration for the drug IBI-10090 is for the treatment of inflammation accompanied by post-operative cataract surgery.
• IBI-10090 is an anti-inflammatory-biodegradable extended-release formulation, injected during eye surgery in the chamber of the eye with the help of Icon’s Varisome drug-delivery technology.
• The increase in the occurrence of cataract diseases and technological advancements in ophthalmic devices drive the market growth. In addition, the hike in the geriatric population worldwide boosts the market growth.
• Need for healthcare insurance and lack of awareness among individuals regarding the benefits impede the growth of the cataract therapeutics market.
• Moreover, the burden of cataract-related diseases is reduced by introducing government programs are lucrative opportunities for key market players.
